Cancer site | ICD-10 | Period of follow-up | ||||||||
≤1984 (35 977 pyr) | 1985–1994 (21 017 pyr) | ≥1995 (60 464 pyr) | ||||||||
Obs. | Ratio | 95% CI | Obs. | Ratio | 95% CI | Obs. | Ratio | 95% CI | ||
All cancers, SIR | C00-C97 | 151 | 1.20 | 1.01 to 1.40 | 151 | 1.18 | 1.00 to 1.39 | 614 | 1.13 | 1.05 to 1.23 |
All cancers, SMR | C00-C97 | 92 | 1.26 | 1.01 to 1.54 | 77 | 1.14 | 0.90 to 1.42 | 207 | 1.00 | 0.87 to 1.15 |
Oesophagus, SIR | C15 | <5 | 1.97 | 0.41 to 5.76 | <5 | 1.49 | 0.18 to 5.37 | 9 | 1.46 | 0.67 to 2.76 |
Oesophagus*, SMR | C15 | <5 | 2.15 | 0.44 to 6.27 | <5 | 1.62 | 0.20 to 5.86 | 9 | 1.76 | 0.81 to 3.35 |
Stomach, SIR | C16 | 16 | 1.35 | 0.77 to 2.20 | 10 | 1.52 | 0.73 to 2.80 | 15 | 1.23 | 0.69 to 2.02 |
Stomach, SMR | C16 | 13 | 1.34 | 0.71 to 2.29 | 9 | 1.74 | 0.79 to 3.29 | 8 | 0.90 | 0.39 to 1.78 |
Colon, SIR | C18 | 17 | 1.96 | 1.14 to 3.15 | 16 | 1.50 | 0.86 to 2.43 | 49 | 1.09 | 0.80 to 1.44 |
Colon, SMR | C18 | 11 | 2.35 | 1.17 to 4.21 | 9 | 1.66 | 0.76 to 3.15 | 15 | 0.79 | 0.44 to 1.30 |
Rectum, rectosigmoid, SIR | C19-C21 | 5 | 0.72 | 0.24 to 1.69 | 6 | 0.80 | 0.29 to 1.73 | 31 | 1.14 | 0.78 to 1.62 |
Rectum, rectosigmoid, SMR | C19-C21 | <5 | 0.82 | 0.17 to 2.38 | <5 | 0.53 | 0.06 to 1.90 | 16 | 1.73 | 0.99 to 2.80 |
Liver, gallbladder, bile ducts, SIR | C22-C24 | 6 | 3.97 | 1.46 to 8.64 | <5 | 2.04 | 0.42 to 5.96 | 6 | 0.87 | 0.32 to 1.89 |
Liver, gallbladder, bile ducts*, SMR | C22-C24 | 5 | 3.46 | 1.12 to 8.08 | <5 | 2.65 | 0.55 to 7.75 | 6 | 1.19 | 0.44 to 2.59 |
Larynx, SIR | C32 | <5 | 0.54 | 0.01 to 3.03 | 5 | 3.31 | 1.08 to 7.73 | 7 | 1.75 | 0.70 to 3.61 |
Larynx, SMR | C32 | <5 | 1.71 | 0.04 to 9.52 | <5 | 2.20 | 0.06 to 12.3 | <5 | 2.46 | 0.51 to 7.20 |
Lung, SIR | C33-C34 | 19 | 1.15 | 0.69 to 1.79 | 22 | 1.33 | 0.83 to 2.01 | 50 | 0.89 | 0.66 to 1.17 |
Lung, SMR | C33-C34 | 15 | 1.07 | 0.60 to 1.76 | 19 | 1.31 | 0.79 to 2.04 | 33 | 0.75 | 0.51 to 1.05 |
Cutaneous melanoma, SIR | C43 | 5 | 1.15 | 0.37 to 2.69 | 11 | 1.95 | 0.97 to 3.48 | 34 | 1.16 | 0.81 to 1.63 |
Cutaneous melanoma, SMR | C43 | <5 | 1.30 | 0.16 to 4.69 | <5 | 2.63 | 0.72 to 6.74 | 7 | 1.17 | 0.47 to 2.40 |
Non-melanoma skin†, SIR | C44 | <5 | 1.05 | 0.22 to 3.08 | <5 | 0.56 | 0.12 to 1.64 | 31 | 1.03 | 0.70 to 1.46 |
Non-melanoma skin†, SMR | C44 | 0 | 0.00 | 0.00 to 14.9 | 0 | 0.00 | 0.00 to 16.8 | <5 | 1.33 | 0.03 to 7.39 |
Mesothelioma, SIR | C45 | <5 | 3.88 | 0.10 to 21.6 | 0 | 0.00 | 0.00 to 5.71 | 7 | 3.04 | 1.22 to 6.26 |
Mesothelioma*, SMR | C45 | <5 | – | 0 | – | <5 | 2.22 | 0.60 to 5.68 | ||
Prostate, SIR | C61 | 15 | 0.81 | 0.45 to 1.33 | 34 | 1.32 | 0.91 to 1.84 | 182 | 1.20 | 1.03 to 1.39 |
Prostate, SMR | C61 | 7 | 0.97 | 0.39 to 1.99 | 7 | 0.65 | 0.26 to 1.33 | 41 | 1.13 | 0.81 to 1.53 |
Testis, SIR | C62 | <5 | 1.53 | 0.42 to 3.92 | 0 | 0.00 | 0.00 to 1.27 | 14 | 1.68 | 0.92 to 2.82 |
Testis, SMR | C62 | 0 | 0.00 | 0.00 to 4.83 | 0 | 0.00 | 0.00 to 23.5 | 0 | 0.00 | 0.00 to 9.63 |
Kidney‡, SIR | C64 | <5 | 0.98 | 0.27 to 2.52 | 9 | 2.51 | 1.15 to 4.77 | 19 | 1.13 | 0.68 to 1.76 |
Kidney‡**, SMR | C64 | <5 | 0.39 | 0.01 to 2.17 | 5 | 2.32 | 0.75 to 5.41 | 6 | 0.93 | 0.34 to 2.02 |
Urinary tract§, SIR | C65-C68 | 15 | 1.50 | 0.84 to 2.48 | 16 | 1.46 | 0.83 to 2.37 | 42 | 1.08 | 0.78 to 1.46 |
Urinary tract§, SMR | C65-C68 | <5 | 1.10 | 0.23 to 3.21 | 5 | 1.83 | 0.59 to 4.27 | 8 | 0.92 | 0.40 to 1.81 |
Thyroid, SIR | C73 | <5 | 1.12 | 0.03 to 6.26 | 0 | 0.00 | 0.00 to 4.71 | 5 | 1.68 | 0.55 to 3.93 |
Thyroid, SMR | C73 | <5 | 4.21 | 0.11 to 23.5 | 0 | 0.00 | 0.00 to 17.0 | <5 | 2.06 | 0.05 to 11.5 |
Hodgkin lymphoma, SIR | C81 | 0 | 0.00 | 0.00 to 2.21 | 0 | 0.00 | 0.00 to 4.97 | <5 | 0.93 | 0.11 to 3.35 |
Hodgkin lymphoma, SMR | C81 | <5 | 1.17 | 0.03 to 6.51 | 0 | 0.00 | 0.00 to 14.6 | 0 | 0.00 | 0.00 to 8.70 |
non-Hodgkin's lymphoma, SIR | C82-C86, C96 | <5 | 0.95 | 0.20 to 2.77 | 7 | 1.86 | 0.75 to 3.84 | 17 | 0.99 | 0.58 to 1.59 |
non-Hodgkin's lymphoma, SMR | C82-C86, C96 | <5 | 0.54 | 0.01 to 3.04 | <5 | 0.94 | 0.11 to 3.40 | 6 | 0.98 | 0.36 to 2.12 |
Multiple myeloma, SIR | C90 | <5 | 1.28 | 0.26 to 3.73 | <5 | 0.96 | 0.12 to 3.45 | 5 | 0.64 | 0.21 to 1.49 |
Multiple myeloma, SMR | C90 | <5 | 1.25 | 0.15 to 4.51 | <5 | 1.90 | 0.39 to 5.56 | <5 | 0.65 | 0.13 to 1.91 |
Leukaemia, SIR | C91-C95 | <5 | 1.09 | 0.30 to 2.78 | <5 | 0.35 | 0.01 to 1.96 | 10 | 0.86 | 0.41 to 1.58 |
Leukaemia, SMR | C91-C95 | <5 | 1.33 | 0.36 to 3.40 | <5 | 0.52 | 0.01 to 2.91 | 7 | 1.19 | 0.48 to 2.45 |
Cells lacking SMR had 0 expected deaths.
Follow-up from 1 January 1960 to 31 December 2018.
*Observed number of deaths corrected to be in line with morphologically confirmed diagnoses, as described in the text (Results, paragraph 3–6).
†Excluding basal cell carcinoma.
‡Excluding renal pelvis.
§Including bladder and renal pelvis.
ICD, International Classification of Diseases; Obs., observed; pyr, person-years.